Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Abstract

In this trial involving patients with metastatic, castration-sensitive prostate cancer, overall survival and radiographic progression-free survival were significantly longer with the addition of apalutamide to ADT than with placebo plus ADT, and the side-effect profile did not differ substantially between the two groups. (Funded by Janssen Research and Development; TITAN ClinicalTrials.gov number, NCT02489318.).

Keywords

Prostate cancerAndrogen deprivation therapyMedicinePlaceboEnzalutamideCastrationOncologyInternal medicineAndrogen receptorAndrogenAntiandrogenUrologyCancerPathologyHormone

Affiliated Institutions

Related Publications

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis , Andrew Martin , Martin R. Stockler +29 more

Enzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer receivin...

2019 New England Journal of Medicine 1481 citations

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

Matthew R. Smith , Fred Saad , Simon Chowdhury +15 more

Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than w...

2018 New England Journal of Medicine 1271 citations

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Johann S. de Bono , Joaquı́n Mateo , Karim Fizazi +17 more

In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role ...

2020 New England Journal of Medicine 2067 citations

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor , Johann S. de Bono , Kim N. +17 more

BACKGROUND: Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic ca...

2021 New England Journal of Medicine 2181 citations

Genomic correlates of clinical outcome in advanced prostate cancer

Wassim Abida , Joanna Cyrta , Glenn Heller +40 more

Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about the impact of...

2019 Proceedings of the National Academy o... 1301 citations

Publication Info

Year: 2019
Type: article
Volume: 381
Issue: 1
Pages: 13-24
Citations: 1384
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1384

OpenAlex

Cite This

APA Style

                            
                                
                                    Kim N., 
                                
                                    Neeraj Agarwal, 
                                
                                    Anders Bjartell
                                
                                et al.
                            
                            (2019). 
                            Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. 
                            New England Journal of Medicine
                            , 381
                            (1)
                            , 13-24.
                            https://doi.org/10.1056/nejmoa1903307
                        

Identifiers

DOI: 10.1056/nejmoa1903307